

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201  
FACSIMILE: 512/536-4598

WRITER'S INTERNET ADDRESS:  
TBOYCE@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:  
512/536-3043

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG



October 3, 2001

FILE: HACK:009US  
10025109

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
October 3, 2001 Date	 Thomas M. Boyce

Commissioner for Patents  
Washington, DC 20231

RE: SN 09/065,082 "HYALURONIC ACID AS DNA CARRIER FOR GENE THERAPY AND VEGF ANTISENSE DNA TO TREAT ABNORMAL RETINAL VASCULARIZATION" - P.E. Rakoczy and I.J. Constable (Client Ref. VS:SJB:BK:FP5962)

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) Amendment: Substitute Specification Under 37 C.F.R. § 1.125(a) to Office Action dated September 6, 2001;
- (2) Substitute Specification; and
- (3) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct or credit said fees from or to Fulbright &

RECEIVED  
OCT 12 2001  
TECH CENTER 1600/2900


Commissioner for Patents

October 3, 2001

Page 2

Jaworski L.L.P. Account No.: 50-1212/10025109/TMB.

Respectfully submitted,

A handwritten signature in cursive script, reading "Thomas M. Boyce". The signature is written in dark ink and is positioned above the printed name.

Thomas M. Boyce

Reg. No. 43,508

TB:SF

Encl.